ACIP releases the 2017 adult and childhood immunization schedules

United States of America
6 February 2017

The CDC and its Advisory Committee on Immunization Practices (ACIP), together with the AAFP and other medical professional organizations, have released the 2017 adult and childhood immunization schedules.

visitor_center.jpg

Changes this year include updated recommendations for a two-dose schedule of nine-valent HPV vaccine (HPV9; Gardasil 9) for patients ages 11-12, a two-dose schedule of meningitis B vaccine (MenB) for adolescents, a clarification regarding recommended adult candidates for hepatitis B (HepB) vaccine and revisions designed to make the adult schedule easier to navigate.

Release of the annual immunization schedules comes amid concerns that the Trump administration has proposed appointing a group to study the safety and effectiveness of vaccines.
In response, AAFP President John Meigs, M.D., of Centreville, Ala., said in a statement: "A new federal commission on immunizations is not necessary and would divert much-needed dollars from other, more pressing health care issues. To suggest the need for such an organization promotes unnecessary, ongoing and disproven skepticism about vaccines and public safety."

Meigs said plainly that vaccines are safe, effective and save lives, further explaining that allegations of a link between vaccines and autism have been thoroughly debunked.
"The science is clear, and family physicians stand ready to help everyone -- from the incoming administration to the general public -- understand how safe and important vaccines are," he stated.

Related News & Events

  • United States of America

    CDC Advisory Committee On Immunization Practices Votes To Recommend Vaxchora, PaxVax’s Single-Dose Oral Cholera Vaccine

    27.06.2016

    The ACIP voted unanimously at their June 22 meeting to recommend Vaxchora for the prevention of toxigenic Vibrio cholerae O1 for travelers to areas of active cholera transmission. The Category A recommendation made by the ACIP for Vaxchora will be forwarded to the director of the CDC and the U.S. Department of Health and Human Services for review and approval. Once approved, the recommendations will be published in the Morbidity and Mortality Weekly Report (MMWR). Category A recommendations are made for all persons in an age- or risk-factor-based group.

    Read more
  • United States of America

    ACIP recommends not to use LAIV During 2016-17 Flu Season

    24.06.2016

    The CDC's Advisory Committee on Immunization Practices (ACIP) held its meeting on June 22-23, 2016. Influenza was on the agenda and ACIP voted to recommend that live attenuated influenza vaccine (LAIV; FluMist), which is licensed for use in people ages 2-49 years, should not be used during the 2016-17 flu season.

    Read more
  • SAGE

    new Interim Recommendations on Vaccination against Ebola Virus Disease from SAGE

    13.05.2019

    Over the last four weeks, the Ebola outbreak in the Eastern Provinces of the Democratic Republic of Congo (DRC) has deteriorated with a large increase in the number of cases1. A major factor in this rise is an increase in critical security incidents that have dramatically affected the ability to identify, follow up and vaccinate contacts successfully. This context challenges the implementation of ring vaccination based on the identification of contacts and contacts of contacts, as recommended by SAGE in April 2017 and confirmed by SAGE during its April 2019 meeting. Further, a potential vaccine shortage may manifest in case the outbreak expands further and/or is prolonged.

    Read more